SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.
Dubois S,Cherblanc F,Belot A,Oberic L,Ghesquières H,Haioun C,Tilly H,Jais J,Jardin F
Source :
Br J Haematol
2026 Sep 27
Pmid / DOI:
42802362
Abstract
Using LYmphoma Study Association clinical trials combining 438 first-line large B-cell lymphomas (LBCL) patients >80 years old, we defined SENIOR-IPI, an easily applicable prognostic index for this elderly population treated with an anti-CD20-miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-based regimen. SENIOR-International Prognostic Index (SENIOR-IPI) takes into account accessible variables (number of aaIPI predictors, lactate dehydrogenase > 3x Upper Limit of Normal (LDH >3× ULN), albumin 80 years old fit for age-adapted immunochemotherapy than IPI, aaIPI and NCCN-IPI.KEYWORDSelderly, large B‐cell lymphoma, prognostic index© 2026 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.